**Appendix 3. Clinical Characteristics and Outcomes of Definite and Probable Cases**

|  |  |
| --- | --- |
| Hospital-onset criteria |  |
| Definite | 7 (6%) |
| Probable | 107 (94%) |
| Symptomatic | 80 (70%) |
| Reason for Testing: |  |
| New symptoms | 47 (41%) |
| Pre-op/Pre-procedure | 27 (24%) |
| Discharge Planning | 27 (24%) |
| Cluster Investigation | 7 (6%) |
| Readmission | 1 (1%) |
| Other | 5 (4%) |
| Received Treatment\* | 60 (53%) |
| Immunocompromised§ | 50 (44%) |
| Unvaccinated | 28 (25%) |
| Outcome: |  |
| Death | 16 (14%) |
| ICU | 14 (12%) |

\*Remdesivir, nirmatrelvir/ritonavir, mAb, or dexamethasone (if new or increased dose for COVID-19)

§Active chemotherapy, hematologic or solid organ transplant, current steroid use of ≥20mg prednisone/day or equivalent